Orchard Therapeutics Announces New OTL-201 Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA) Accepted for Oral Presentation at 62nd American Society of Hematology Annual Meeting
05 nov. 2020 07h00 HE
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the presentation of new clinical data at the...
Orchard Therapeutics Reviews Recent Portfolio Progress and Reports Third Quarter 2020 Financial Results
03 nov. 2020 07h00 HE
|
Orchard Therapeutics (Europe) Limited
Libmeldy TM Receives Positive CHMP Opinion for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD); U.S. IND Application on Track for Year End 2020 Cash and Investments of More Than $200M...
Orchard Therapeutics to Host Virtual R&D Investor Event on Friday, November 13, 2020
02 nov. 2020 07h00 HE
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will webcast a virtual R&D event ‘New...
Orchard Therapeutics CEO Bobby Gaspar, M.D., Ph.D., Appointed to the Alliance for Regenerative Medicine’s 2021 Board of Directors
22 oct. 2020 07h00 HE
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company’s chief executive officer, Bobby...
Orchard Therapeutics Receives Positive CHMP Opinion for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)
16 oct. 2020 06h00 HE
|
Orchard Therapeutics (Europe) Limited
First therapy recommended for full marketing authorization in the EU for eligible patients with confirmed diagnosis of late infantile or early juvenile MLD variants One-time treatment with Libmeldy...
Orchard Therapeutics Receives EMA PRIME Designation for OTL-203 for the Treatment of MPS-I
28 sept. 2020 07h00 HE
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the European Medicines Agency (EMA) has granted Priority...
Orchard Therapeutics to Present at Upcoming Virtual Investor Conferences
09 sept. 2020 07h00 HE
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the following...
Orchard Therapeutics Announces Additional Interim Results from Proof-of-Concept Study of OTL-203 for MPS-I
01 sept. 2020 07h00 HE
|
Orchard Therapeutics (Europe) Limited
Data on all eight patients demonstrate sustained engraftment and supranormal IDUA enzyme expression Translation of metabolic correction to clinical outcomes in first two patients continues to support...
Orchard Therapeutics Announces Clinical Data Presentations at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
24 août 2020 07h00 HE
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced presentations at the upcoming 46th Annual Meeting of...
Orchard Therapeutics Advances New Strategic Plan and Reports Second Quarter 2020 Financial Results
06 août 2020 07h00 HE
|
Orchard Therapeutics (Europe) Limited
Regulatory and Clinical Progress in MLD, MPS-I and MPS-IIIA Illustrate Execution in Neurometabolic Disorders; EU Regulatory Decision for Libmeldy™ Expected in 2H 2020 MolMed and GSK Agreements...